$BHC and $TEVA are falling today because congressional hearings investigating drug pricing are hurting those with high debt. And BHC, TEVA have plenty of debt.What they need is cash flow growth from strong drug prices. If that is not available, these stocks will underperform and tread water. $TEVA, Teva Pharmaceutical Industries Limited / H1 $BHC, Bausch Health Companies Inc. / H1 The good news for BHC is that it bought Synergy $SGYP for $195M plus other liabilities. Here's the PR.BHC has a good sales force to grow TRULANCE sales. If it can pull off what Synergy could not, BHC may have a winning asset.